Señales en vivo de BLUE | Maximiza tus Ganancias con Getagraph.com

VENDER 118810 min ago

@ $1.019

Emitido: 14 feb 2024 @ 09:30

Retorno: -1.84%

Señal anterior: feb 12 - 12:12

Señal anterior: Comprar

Retorno: -3.90 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	19.89M
Volumen promedio	8.20M
Capitalización de mercado	192.74M
EPS	$0 ( 2024-04-03 )
Próxima fecha de ganancias	( $-0.470 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.590
ATR14	$0.0100 (1.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Colvin Richard A	Buy	199 000	Stock Option (right to buy)
2024-03-01	Colvin Richard A	Sell	6 770	Common Stock
2024-03-01	Vittiglio Joseph	Buy	199 000	Stock Option (right to buy)
2024-03-01	Obenshain Andrew	Buy	650 000	Stock Option (right to buy)
2024-03-04	Obenshain Andrew	Sell	6 095	Common Stock

INSIDER POWER
92.34
Last 95 transactions
Buy: 3 237 593 \| Sell: 214 711

Volumen Correlación

Largo: -0.31 (neutral)

Corto: -0.99 (very strong negative)

Signal:(36.861) Neutral

bluebird bio Inc Correlación

10 Correlaciones Más Positivas
ALXO	0.973
YJ	0.949
ORPH	0.947
PMVP	0.946
CSSEP	0.946
KNSA	0.945
NAKD	0.944
GOOD	0.944
IPA	0.943
GSMG	0.942

10 Correlaciones Más Negativas
CPAQ	-0.961
MCAA	-0.958
SCOB	-0.957
LGACU	-0.957
ABGI	-0.957
FICV	-0.957
AGGR	-0.957
LGAC	-0.957
LVRA	-0.955
KAII	-0.955

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

bluebird bio Inc Correlación - Moneda/Commodity

-0.18
( neutral )

-0.36
( neutral )

0.00
( neutral )

0.07
( neutral )

bluebird bio Inc Finanzas

Annual	2022
Ingresos:	$3.60M
Beneficio Bruto:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2022
Ingresos:	$3.60M
Beneficio Bruto:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2021
Ingresos:	$3.66M
Beneficio Bruto:	$-35.20M (-961.09 %)
EPS:	$-11.89

FY	2020
Ingresos:	$250.73M
Beneficio Bruto:	$245.34M (97.85 %)
EPS:	$-9.95

Financial Reports:

No articles found.

bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.